Qiagen N.V. logo QGEN - Qiagen N.V.

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 12
HOLD 18
SELL 0
STRONG
SELL
0
| PRICE TARGET: $45.17 DETAILS
HIGH: $59.00
LOW: $36.00
MEDIAN: $43.00
CONSENSUS: $45.17
UPSIDE: 28.43%

About Qiagen N.V. (https://www.qiagen.com)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Key Executives

NAME TITLE DOB SALARY
Thierry Bernard Chief Executive Officer, MD & Member of Management Board 1964 $2,429,949 USD
Roland Sackers Chief Financial Officer, MD & Member of Management Board 1968 $1,329,050 USD
Antonio Santos Senior Vice President & Head of Global Operations
Daniel Wendorff CEFA CIIA VP & Head of Investor Relations
Dominic John Vice President of Marketing & Product Management
Jean-Pascal Viola Senior Vice President & Head of Corporate Strategy and Business Development
John Gilardi Vice President & Head of Corporate Communications
Jonathan G. Sheldon Senior Vice President & Head of the QIAGEN Digital Insights Business Area 1972
Nitin Sood Senior VP & Head of Product Portfolio & Innovation 1973
Stephany Foster Senior Vice President & Head of Human Resources 1979
Thomas Schweins Senior Vice President of Life Science Business Area
Thomas Theuringer Senior Director & Head of External Communications

Company Peers

Peer analysis pending, check back in 1-2 minutes.